HomeInsightsStock Comparison

Glenmark Pharmaceuticals Ltd vs Lupin Ltd Stock Comparison

Glenmark Pharmaceuticals Ltd vs Lupin Ltd Stock Comparison

Last Updated on: May 29, 2025

Key Highlights

  • The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 1389 as of 29 May 12:10.
  • The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 38.5 on March 2024 . This represents a CAGR of 0.26% over 4 years.
  • The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 27019 crore on March 2024 . This represents a CAGR of 35.97% over 5 yearsThe Market Cap of Lupin Ltd changed from ₹ 26713 crore on March 2020 to ₹ 73722 crore on March 2024 . This represents a CAGR of 22.51% over 5 years.
  • The revenue of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 3267 crore as compare to the Dec '24 revenue of ₹ 3418 crore. This represent the decline of -4.41% The revenue of Lupin Ltd for the Mar '25 is ₹ 5724 crore as compare to the Dec '24 revenue of ₹ 5821 crore. This represent the decline of -1.67%.
  • The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 199.89 crore as compare to the Dec '24 ebitda of ₹ 631.36 crore. This represent the decline of -68.34% The ebitda of Lupin Ltd for the Mar '25 is ₹ 1378 crore as compare to the Dec '24 ebitda of ₹ 1409 crore. This represent the decline of -2.23%.
  • The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 4.38 crore over 8 quarters. This represents a CAGR of -84.09% The net profit of Lupin Ltd changed from ₹ 453.33 crore to ₹ 782.38 crore over 8 quarters. This represents a CAGR of 31.37% .
  • The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 1.37 % on March 2024 . This represents a CAGR of -23.44% over 5 yearsThe Dividend Payout of Lupin Ltd changed from 37.36 % on March 2020 to 15.67 % on March 2024 . This represents a CAGR of -15.95% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.
  • The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland.

About Lupin Ltd

  • Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
  • The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
  • In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
  • In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

Glenmark Pharmaceuticals Ltd News Hub

News

Board of Glenmark Pharmaceuticals recommends final dividend

Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeti...

Read more

24 May 2025 11:52

News

Glenmark Pharmaceuticals grants 1.19 lakh stock options under ESOS

The Board of Glenmark Pharmaceuticals at its meeting held on 22 May 2025 has granted 1,19,...

Read more

22 May 2025 16:03

News

Glenmark Pharmaceuticals announces board meeting date

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2...

Read more

13 May 2025 15:58

News

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001

IGI (Ichnos Glenmark Innovation), a global, fully integrated clinical-stage biotechnology ...

Read more

05 May 2025 19:16

News

Glenmark Pharma's US arm set to launch generic Adderall tablets

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroampheta...

Read more

17 Apr 2025 08:04

News

Glenmark Pharmaceuticals allots 12,653 equity shares under ESOP

Glenmark Pharmaceuticals has allotted 12,653 equity shares under ESOP. Consequently, the p...

Read more

17 Apr 2025 20:08

Lupin Ltd News Hub

News

Lupin allots 78,930 equity shares under ESOP

Lupin has allotted 78,930 equity shares under Stock Option plans of the Company. According...

Read more

27 May 2025 15:33

News

Lupin grants 7,337 stock options

Lupin has granted 7,337 stock options on 27 May 2025. Please note that upon vesting, one s...

Read more

27 May 2025 18:42

News

Lupin enters into license and supply agreement with SteinCares

Lupin has entered into a license and supply agreement with SteinCares, a leading specialty...

Read more

26 May 2025 10:27

News

Lupin to develop next-gen inhalers using Honeywell's Solstice' Air propellant

Lupin announced today its plan to use Honeywell's Solstice' Air (HFO-1234ze cGMP) propella...

Read more

20 May 2025 19:07

News

Board of Lupin recommends final dividend

Lupin announced that the Board of Directors of the Company at its meeting held on 14 May 2...

Read more

15 May 2025 10:06

News

Lupin receives USFDA approval for Rivaroxaban Tablets

Lupin announced that it has received approval from the United States Food and Drug Adminis...

Read more

15 May 2025 16:21

SWOT Analysis Of Lupin Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Lupin Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Lupin Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Lupin Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 38,926 Cr while Market cap of Lupin Ltd is 88,661 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Lupin Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Lupin Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Lupin Ltd?

As of May 29, 2025, the Glenmark Pharmaceuticals Ltd stock price is INR ₹1379.4. On the other hand, Lupin Ltd stock price is INR ₹1941.7.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Lupin Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Lupin Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions